TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19473560
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection with triamcinolone hexacetonide 60 mg and xylocaine chloride 2% (IAI group)
Study: 19473560
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of triamcinolone acetonide 60 mg and xylocaine chloride 2% (IM group)
Study: 12374678
Drug: Oral alpha-difluoromethylornithine
Normalized name: alpha-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alpha-difluoromethylornithine (DFMO) 0.5 g/m(2)/day for 6 months
Study: 2154068
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin infusions (500 mg/kg x 3 doses, followed by 250 mg/kg x 2 doses at 2-week intervals)
Study: 7276205
Drug: Distalgesic (paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distalgesic (paracetamol and dextropropoxyphene)
Study: 28884989
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg daily for 12 weeks
Study: 19700936
Drug: Leukotriene receptor
Normalized name: Leukotriene receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene receptor antagonist (LTRA)
Study: 25872950
Drug: Five weekly
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five weekly psychosocial interventions based on cognitive behavioral therapy (CBT) in combination with early palliative care (PC)
Study: 19763132
Drug: losartan/hydrochlorothiazide (L/HCTZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan/hydrochlorothiazide (L/HCTZ)
Study: 17088140
Drug: Reslizumab at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reslizumab at 3 mg/kg
Study: 17088140
Drug: Reslizumab at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reslizumab at 1 mg/kg
Study: 7967420
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 2 therapy courses for completely resected patients (branch R1)
Study: 7967420
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 4 therapy courses for patients with extra-abdominal localization or abdominal localization and LDH < 500 U/l (branch R2)
Study: 7967420
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 6 therapy courses for patients with abdominal localization and LDH >= 500 U/l (branch R3)
Study: 7967420
Drug: Intensification therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification therapy for patients with incomplete response after 2 courses
Study: 7967420
Drug: CNS chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CNS chemotherapy for CNS positive patients
Study: 7967420
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of pEFS for stage III abdominal disease and LDH >= 500 U/l
Study: 2889307
Drug: Idazoxan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (20 mg po, three times a day)
Study: 23116214
Drug: Unani formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unani formulation for ulcer healing
Study: 12358335
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone (BDP) at doses of 50, 100, 200, or 500 microg x day(‐1) for eight weeks
Study: 10076146
Drug: Carbetocin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (100 microg single dose)
Study: 10076146
Drug: Oxytocin (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (standard 8-hour infusion)
Study: 7572651
Drug: Enalapril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (1 mg intravenous, followed by oral therapy)
Study: 2404556
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) and heparin; 1 g 5-FU and 5000 U heparin daily for 7 days
Study: 6102865
Drug: Triclofos 70
Normalized name: Triclofos
DrugBank: Triclofos (DB06753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triclofos 70 mg kg‐1 + atropine 0.03 mg kg‐1
Study: 6102865
Drug: Diazepam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.25 mg kg‐1 + atropine 0.03 mg kg‐1
Study: 6102865
Drug: Flunitrazepam 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.02 mg kg‐1 + atropine 0.03 mg kg‐1
Study: 6102865
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs (Triclofos, Diazepam, Flunitrazepam)
Study: 6102865
Drug: Triclofos 70
Normalized name: Triclofos
DrugBank: Triclofos (DB06753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triclofos 70 mg kg‐1
Study: 6102865
Drug: Diazepam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.25 mg kg‐1 and Flunitrazepam 0.02 mg kg‐1
Study: 27415612
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg rosuvastatin (R group, n=26)
Study: 27415612
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin plus 2 g of ω-3 PUFAs (R + O group, n=24)
Study: 24553480
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral syrup containing paracetamol, phenylephrine hydrochloride, and guaifenesin
Study: 24553480
Drug: Reference oral
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference oral liquid formulation
Study: 24553480
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral syrup
Study: 22442826
Drug: Vildagliptin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (all doses)
Study: 20980796
Drug: ZOSTAVAX® (zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZOSTAVAX® (zoster vaccine) administered concomitantly with PNEUMOVAX® 23 (pneumococcal vaccine)
Study: 20980796
Drug: PNEUMOVAX® 23
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNEUMOVAX® 23 (pneumococcal vaccine) administered concomitantly with ZOSTAVAX®
Study: 20980796
Drug: ZOSTAVAX® (zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZOSTAVAX® (zoster vaccine) administered nonconcomitantly with PNEUMOVAX® 23 (pneumococcal vaccine)
Study: 12635061
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (2‐4 microg/kg/min) with isoflurane supplementation
Study: 12635061
Drug: Remifentanil continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil continuous infusions (1‐5 microg/kg/min)
Study: 1734554
Drug: Tampons impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tampons impregnated with tranexamic acid (TA), three tampons administered at 2-hourly intervals over 6 hours
Study: 25436480
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment for simple bone cysts (exact intervention details not provided)
Study: 25436480
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment for simple bone cysts
Study: 22437191
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus BMX 54 (vaginal application, one tablet once a week for 12 weeks)
Study: 18327969
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of anesthetic solution
Study: 18327969
Drug: 3.6 mL
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mL of anesthetic solution
Study: 12797909
Drug: ACE-Inhibitors (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-Inhibitors (group 1)
Study: 12797909
Drug: Diuretics (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (group 2)
Study: 12797909
Drug: Ca-Antagonists (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca-Antagonists (group 3)
Study: 10334671
Drug: Normalization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normalization of haemoglobin (target 13.5-16.0 g/dl)
Study: 10334671
Drug: Normalization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normalization of haemoglobin (target 13.0-14.0 g/dl)
Study: 10334671
Drug: Increase haemoglobin
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase haemoglobin to a mean of 12.5 g/dl
Study: 10334671
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (target haemoglobin 9.5-10.5 g/dl)
Study: 8729309
Drug: Buprenorphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.3 mg subcutaneous) on demand (group 1, n = 20)
Study: 8729309
Drug: Buprenorphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.3 mg)‐propacetamol (2 g)‐ketoprofen (100 mg) by intravenous route over 2 hours followed by an infusion of propacetamol (2 g) and ketoprofen (100 mg) at a constant rate over 22 hours (group 2, n = 20)
Study: 8729309
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of buprenorphine (0.3 mg), propacetamol (2 g) and ketoprofen (100 mg) over the same period (group 3, n = 20)
Study: 27386642
Drug: Yiguanjian Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiguanjian Decoction (YD) combined with Adefovir Dipivoxil Tablet (ADT)
Study: 27386642
Drug: Adefovir Dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir Dipivoxil Tablet (ADT) alone
Study: 9220875
Drug: Pain management
Normalized name: Olu Pain Management 4%-1% Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain management strategies and medications at hospital admission
Study: 9220875
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antiseptics vs cleansing solutions
Study: 9220875
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of non-recommended treatments for ulcers
Study: 8193690
Drug: HBOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC vaccine
Study: 3812345
Drug: Lowest selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest selenium quintile (< 105.0 micrograms/L)
Study: 30153780
Drug: Histamine-2 Receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine-2 Receptor Blockers (H2RB)
Study: 24552184
Drug: IN.PACT Amphirion™
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN.PACT Amphirion™ paclitaxel drug-eluting balloon (IA-DEB)
Study: 22681643
Drug: Urethral sparing
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urethral sparing intensity modulated radiation therapy (US‐IMRT)
Study: 22681643
Drug: Standard intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intensity modulated radiation therapy (S‐IMRT)
Study: 17667137
Drug: Oral mefenamic
Normalized name: meclofenamate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mefenamic acid and intramuscular meperidine
Study: 11452896
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg slow release dipyridamole (DP)
Study: 11452896
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ASA plus DP
Study: 3288723
Drug: High-dose pentobarbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pentobarbital
Study: 31657275
Drug: High DCI
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High DCI content group (550 mg MYO + 300 mg DCI daily)
Study: 31657275
Drug: Low DCI
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low DCI content group (550 mg MYO + 27.6 mg DCI daily)
Study: 30019528
Drug: dHACA (dehydrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: dHACA (dehydrated human amnion and chorion allograft) applied weekly for up to 12 weeks
Study: 24265819
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses group (20 μg IM at months 0, 1, and 6)
Study: 24265819
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses group (20 μg IM at months 0, 1, 2, 6)
Study: 24265819
Drug: Four double
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four double doses group (40 μg IM at months 0, 1, 2, 6)
Study: 24265819
Drug: Four double
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four double doses group
Study: 10877734
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of rofecoxib, 250 mg
Study: 10877734
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of indomethacin, 75 mg
Study: 10877734
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of rofecoxib, 12.5 mg/d
Study: 10877734
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of rofecoxib, 25 mg/d
Study: 10877734
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of indomethacin, 50 mg three times daily
Study: 9106016
Drug: Azithromycin 3-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 3-day course (10 mg/kg daily)
Study: 9106016
Drug: Azithromycin 5-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 5-day course (10 mg/kg on day 1 and 5 mg/kg on days 2‐5)
Study: 3492153
Drug: Nimodipine (0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (0.09 mg/kg X h)
Study: 28560802
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg prednisolone
Study: 20981001
Drug: Endoxifen, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoxifen, single oral doses ranging from 0.5 to 4.0 mg
Study: 11850257
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of amprenavir with 100 mg of ritonavir twice daily
Study: 11850257
Drug: Once-daily regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily regimens
Study: 84259
Drug: Alternate-day prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternate-day prednisone (35 mg/m2/48 h)
Study: 84259
Drug: Intermittent prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent prednisone (40 mg/m2 on three consecutive days out of seven)
Study: 31107694
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine Training (TCMT) for 12 weeks
Study: 20869706
Drug: GnRH agonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonists combined with GnRH antagonists
Study: 20869706
Drug: GnRH agonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonists alone
Study: 19560257
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) 2000 mg/100 ml of saline
Study: 19560257
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) 100 ml of saline
Study: 15001970
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (300 mg tablet, 3 times daily for 14 days)
Study: 3544754
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nisoldipine
Study: 3544754
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nisoldipine
Study: 31176375
Drug: High-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow oxygen therapy (HFOT) during high-intensity exercise training
Study: 15527158
Drug: Community-based directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based directly observed treatment (DOT) using guardians and former TB patients
Study: 15527158
Drug: Health facility-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health facility-based directly observed treatment (DOT)
Study: 8267425
Drug: EC +
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC + BN 52021 (10 mg/kg)
Study: 8267425
Drug: EC (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC (40 mL/kg)
Study: 30871934
Drug: Nestorone (NES)
Normalized name: Ne
DrugBank: Segesterone acetate (DB14583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone (NES) 200 mcg/day and estradiol (E2) 10 mcg/day
Study: 30871934
Drug: Nestorone (NES)
Normalized name: Ne
DrugBank: Segesterone acetate (DB14583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone (NES) 200 mcg/day and estradiol (E2) 20 mcg/day
Study: 30871934
Drug: Nestorone (NES)
Normalized name: Ne
DrugBank: Segesterone acetate (DB14583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone (NES) 200 mcg/day and estradiol (E2) 40 mcg/day
Study: 27887033
Drug: Menthol gel
Normalized name: MENTHOL GEL,TOP
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol gel
Study: 27887033
Drug: Reference treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference treatments (0.9% saline and marketed gel 1% diclofenac, Voltaren)
Study: 23740384
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml LZD suspension
Study: 23740384
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg LZD tablet
Study: 17162142
Drug: Usual-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-protein diet (1.3 g/kg/d)
Study: 14572566
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L sulfate‐free electrolyte lavage solution (SF‐ELS) plus 20 mg p.o. bisacodyl
Study: 14572566
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L sulfate-free electrolyte lavage solution (SF‐ELS)
Study: 2202247
Drug: Furosemide 30
Normalized name: furosemide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 30 mg
Study: 20018483
Drug: Probiotic supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplemented formula (Lactobacillus salivarius CECT5713, 2 × 10(6) cfu/g)
Study: 15941684
Drug: Glucan treatment
Normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucan treatment for 12 weeks
Study: 10848657
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d.
Study: 16817839
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg o.d.
Study: 789219
Drug: Frubienzym (throat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frubienzym (throat lozenges with 5 mg lysozyme, 2 mg papaine and 200 I.U. bacitracin)
Study: 23801589
Drug: CALM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALM treatment
Study: 21777477
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (including psychotherapy, pharmaceutical interventions, and group therapy)
Study: 19623867
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (30-50 mg/kg bolus followed by 500 mg/h continuous infusion)
Study: 19623867
Drug: Isotonic solution
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic solution (control group)
Study: 17101743
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg daily
Study: 17101743
Drug: Varenicline 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 2 mg daily
Study: 17101743
Drug: Varenicline 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 3 mg daily
Study: 17101743
Drug: Varenicline 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 2 mg twice daily
Study: 11498066
Drug: Oral crystalline
Normalized name: Mesembryanthemum crystallinum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral crystalline cyanocobalamin (3000 microg or 5000 microg once a week for at least 3 months)
Study: 325301
Drug: Guancydine (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guancydine (21 mg/kg body weight for 7 to 18 days)
Study: 24796764
Drug: CC/IUI (Clomiphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC/IUI (Clomiphene Citrate/Intrauterine Insemination)
Study: 24796764
Drug: FSH/IUI (Follicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH/IUI (Follicle Stimulating Hormone/Intrauterine Insemination)
Study: 15670788
Drug: Haplotype V3‐V4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haplotype V3‐V4 (G‐C)
Study: 12765846
Drug: n‐3 fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 fatty acid supplementation (3.6g n‐3 fatty acids/day containing 2.4 g of EPA and DHA)
Study: 10580781
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment groups (hormone therapy)
Study: 26232241
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate once-monthly (PP)
Study: 3106234
Drug: Pseudomonas immunoglobulin
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas immunoglobulin (250 mg/kg body weight, intravenous route, days 3 to 13)
Study: 29746282
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 500 mg daily
Study: 27039242
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in relative abundance of insulin-like growth factor binding proteins (IGFBPs) and subclasses of apolipoprotein (Apo) and transthyretin